2 active not recruiting, 2 completed, 1 unknown. 2 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Inclusion Body Myositis (IBM): new trials by email Literature Review of Inclusion Body Myositis (IBM) trials Research Report on Inclusion Body Myositis (IBM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each Condition Inclusion Body Myositis (IBM), Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Active not recruiting | IRCCS San Raffaele | 30 | 2026-07-01 | 2026-09-01 | |
| Exercise as Treatment for Patients With Inclusion Body Myositis Exercise group in a hospital setting - Inclusion Body Myositis (IBM), Feasibility Study | Not applicable | Completed | Oslo University Hospital | 15 | 2025-01-06 | 2025-06-24 |
| Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis Ulviprubart (ABC008) - Inclusion Body Myositis (IBM) | Phase 2 / Phase 3 | Active not recruiting | Abcuro, Inc. | 270 | 2024-10-21 | 2025-07-28 |
| Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Rapamycin, Placebo - Inclusion Body Myositis (IBM) | Phase 2 / Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 44 | 2015-07-15 | 2025-09-02 |
| Natalizumab in Inclusion Body Myositis (IBM) Natalizumab - Inclusion Body Myositis (IBM) | Phase 1 | Unknown | Phoenix Neurological Associates, LTD | 6 | 2013-05-01 | 2017-02-09 |
Myositis, Inclusion Body (5) · Amyotrophic Lateral Sclerosis (1) · Motor Activity (1)
Muscular Diseases (5) · Musculoskeletal Diseases (5) · Myositis (5) · Nervous System Diseases (5) · Neuromuscular Diseases (5) · Behavior (1) · Central Nervous System Diseases (1) · Metabolic Diseases (1) · Motor Neuron Disease (1) · Neurodegenerative Diseases (1) · Nutritional and Metabolic Diseases (1) · Proteostasis Deficiencies (1) · Spinal Cord Diseases (1) · TDP-43 Proteinopathies (1)
Natalizumab (1) · Sirolimus (1)
Abcuro, Inc. (1) · IRCCS San Raffaele (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Oslo University Hospital (1) · Phoenix Neurological Associates, LTD (1)
United States (2) · Australia (1) · France (1) · Italy (1) · Norway (1)
Todd Leveine, MD (1)